Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells

Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation

(2020) Johan G. Schnitzler et al.   CIRCULATION RESEARCH

Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1

(2020) Ghazaleh Behnammanesh et al.   Redox Biology

Delayed ischemic contracture onset by Empagliflozin associates with NHE-1 inhibition and is dependent on insulin in isolated mouse hearts

(2019) Laween Uthman et al.   CARDIOVASCULAR RESEARCH

CTRP3 Alleviates Ox-LDL–Induced Inflammatory Response and Endothelial Dysfunction in Mouse Aortic Endothelial Cells by Activating the PI3K/Akt/eNOS Pathway

(2019) Lei Chen et al.   INFLAMMATION

The origin of heterogeneous nanoparticle uptake by cells

(2019) Paul Rees et al.   Nature Communications

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway

(2019) Qingguo Lu et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells

(2018) Chenke Xu et al.   BIOCHEMICAL PHARMACOLOGY

SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice

(2018) Dustin M. Lee et al.   Cardiovascular Diabetology

Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor α-mediated activation

(2018) Wojciech Garczorz et al.   Cardiovascular Therapeutics

Reciprocal regulation of eNOS and caveolin-1 functions in endothelial cells

(2018) Zhenlong Chen et al.   MOLECULAR BIOLOGY OF THE CELL

AMP-Activated Protein Kinase Regulation of the NLRP3 Inflammasome during Aging

(2018) Mario D. Cordero et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress

(2018) Mahmoud El-Daly et al.   VASCULAR PHARMACOLOGY

Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms

(2018) Sarah J. Mancini et al.   Scientific Reports

Helium alters the cytoskeleton and decreases permeability in endothelial cells cultured in vitro through a pathway involving Caveolin-1

(2018) Kirsten F. Smit et al.   Scientific Reports

Hexokinase 2 as a novel selective metabolic target for rheumatoid arthritis

(2018) Marta F Bustamante et al.   ANNALS OF THE RHEUMATIC DISEASES

Toll-like Receptor 4–Induced Glycolytic Burst in Human Monocyte-Derived Dendritic Cells Results from p38-Dependent Stabilization of HIF-1α and Increased Hexokinase II Expression

(2018) Laure Perrin-Cocon et al.   JOURNAL OF IMMUNOLOGY

Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation

(2018) Yumei Ye et al.   CARDIOVASCULAR DRUGS AND THERAPY

Hyperbaric oxygen boosts long noncoding RNA MALAT1 exosome secretion to suppress microRNA-92a expression in therapeutic angiogenesis

(2018) Kou-Gi Shyu et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients

(2018) Laween Uthman et al.   Frontiers in Physiology

Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake

(2017) Kosuke Kaji et al.   INTERNATIONAL JOURNAL OF CANCER

Enhanced Glycolytic Metabolism Contributes to Cardiac Dysfunction in Polymicrobial Sepsis

(2017) Zhibo Zheng et al.   JOURNAL OF INFECTIOUS DISEASES

Acute detachment of hexokinase II from mitochondria modestly increases oxygen consumption of the intact mouse heart

(2017) Rianne Nederlof et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects

(2017) Ioanna Andreadou et al.   Frontiers in Physiology

Exploring Non-Metabolic Functions of Glycolytic Enzymes in Immunity

(2017) Scott M. Seki et al.   Frontiers in Immunology

Cyclophilin D ablation is associated with increased end-ischemic mitochondrial hexokinase activity

(2017) Rianne Nederlof et al.   Scientific Reports

Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes

(2016) Andrew O. Odegaard et al.   Cardiovascular Diabetology

The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels

(2016) Simon A. Hawley et al.   DIABETES

Effect of helium pre- or postconditioning on signal transduction kinases in patients undergoing coronary artery bypass graft surgery

(2016) Kirsten F. Smit et al.   Journal of Translational Medicine

AMPK Suppresses Vascular Inflammation In Vivo by Inhibiting Signal Transducer and Activator of Transcription-1

(2015) Chaoyong He et al.   DIABETES

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKɛ supports the anabolic demands of dendritic cell activation

(2014) Bart Everts et al.   NATURE IMMUNOLOGY

The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity

(2014) Matthias Oelze et al.   PLoS One

The Warburg effect then and now: From cancer to inflammatory diseases

(2013) Eva M. Palsson-McDermott et al.   BIOESSAYS

A Novel Paradigm for Heart Failure With Preserved Ejection Fraction

(2013) Walter J. Paulus et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Succinate is an inflammatory signal that induces IL-1β through HIF-1α

(2013) G. M. Tannahill et al.   NATURE

Amiloride attenuates lipopolysaccharide-accelerated atherosclerosis via inhibition of NHE1-dependent endothelial cell apoptosis

(2012) Gui-mei Cui et al.   ACTA PHARMACOLOGICA SINICA

Mitochondrial hexokinase II (HKII) and phosphoprotein enriched in astrocytes (PEA15) form a molecular switch governing cellular fate depending on the metabolic state

(2012) P. Mergenthaler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet-Induced Obesity and Diabetes in Mice

(2008) P. D. Cani et al.   DIABETES